Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Blood and bone marrow cell collection.
- Who it may be relevant to
- Registry conditions: Osteoporosis, Osteoarthritis, Hip, Hip Fractures, Clonal Hematopoiesis of Indeterminate Potential. Basic parameters: from 55 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Belgium
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP): a Prospective Observational Study
Overview
Bone marrow samples will be collected from patients undergoing hip arthroplasty surgery. Blood and bone marrow samples will be used for metabolic profiling and analysis of relevant CHIP mutations. Combined single-cell transcriptomics and mutation-specific single-cell genotyping (biotin-PCR using mutation-targeted primers followed by sequencing) will subsequently be performed. The gene expression profile of wildtype and mutant hematopoietic stem cells will be compared, performing both broad gene set enrichment analysis and targeted analysis of metabolic pathways.
Interventions
- Other Blood and bone marrow cell collection
Collection of blood and bone marrow
Primary outcome measures
- Gene Set Enrichment Analysis (GSEA) Normalized Enrichment Score (NES) [Time frame: One day]
Eligibility criteria
Inclusion criteria
- Age 65 years and older
Exclusion criteria
- known haematological condition (myelodysplasia, leukemia, cancer)
- inability to provide written informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-control
Study locations
Belgium · 1 center
- Imelda Hospital — Bonheiden
Identifiers
NCT: NCT05246813 · 20211214